Oklahoma Medical Research Foundation

Investment governance likely falls under President and CEO Andrew S. Weyrich and the board chaired by Len Cason. OMRF does not publicly name a dedicated CIO or investment committee, and the small endowment size suggests a lean internal allocation team supplemented by external fund relationships. Day-to-day management of the venture-stage spin-out activity runs through the partnership with i2E and the Accele BioPharma vehicle.

OMRF sources direct investments from its own laboratory discoveries and through its partnerships with i2E and the Presbyterian Health Foundation. Accele BioPharma, co-founded with the Presbyterian Health Foundation, acts as an incubator to advance OMRF-derived biotech toward commercialization. This proprietary pipeline is not broadly accessible to outside co-investors unless structured through i2E-led rounds.

OMRF operates both sides. The endowment holds a fund-of-funds posture across private equity, hedge fund, and real estate fund commitments, mostly US-based for PE and real estate and global for hedge funds. It also writes direct early-stage checks, including seed and startup rounds, for Oklahoma-based biotech spinning out of OMRF labs.

The Presbyterian Health Foundation is a co-investor and business partner. Together they co-founded Accele BioPharma, an accelerator designed to move OMRF discoveries toward clinical application. The foundation is also a frequent co-funder of Oklahoma City biotech initiatives, and both entities operate within the same innovation district adjacent to the University of Oklahoma Health Sciences Center.

OMRF is itself a 501(c)(3) nonprofit biomedical research foundation, and its investment portfolio is the endowment used to support that mission. There is no separate philanthropic vehicle named in public records, but the foundation's commercial real estate holdings and mineral interests are held through OMRF Real Estate LLC and other wholly-owned structures, suggesting a formal separation of operating and investment assets.

OMRF's direct venture activity is limited to healthcare services and biotechnology, specifically commercializing its own research on cancer, heart disease, autoimmune disorders, and aging. The foundation does not appear to pursue direct investments in software, consumer, energy transition, or other non-healthcare verticals, concentrating its operational and investment resources on the life sciences.

OMRF targets the earliest stages of company formation — seed, startup, and early-stage rounds — through its technology transfer and spin-out partnerships. The Accele BioPharma incubator model suggests involvement from pre-incorporation through Series A. Later-stage expansion and growth capital is likely accessed through the endowment's fund commitments rather than direct balance-sheet checks.